Chemical formula: C₃₇H₅₉N₅O₉PdS Molecular mass: 840.26 g/mol
Padeliporfin is retained within the vascular system. When activated with 753 nm wavelength laser light, padeliporfin triggers a cascade of pathophysiological events resulting in focal necrosis within a few days.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L01XD07 | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XD Sensitizers used in photodynamic/radiation therapy | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| TOOKAD Powder for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Padeliporfin is an active ingredient of these brands:
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Ireland (IE)
Italy (IT)
Lithuania (LT)
Poland (PL)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
